TIDMSENS
RNS Number : 1623H
Sensyne Health PLC
02 August 2021
Sensyne grows medical research dataset to 60 million
patients
Deep longitudinal, disease agnostic structured global dataset,
covering over 4,000 indications will industrialise Sensyne's life
sciences activities
Oxford, U.K. 02 August 2021: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company" or the "Group"), the ethical Clinical
AI company, today announces that it has reached a milestone of
access to a combined clinical research, clinical trial and real
world de-identified and anonymised dataset of over 60 million
patients. This enlarged dataset results from both Sensyne's
investment in virtual clinical development company, Phesi Inc. in
January 2021, and the progress made by Sensyne and Phesi in
building their respective data platforms.
Between December 2020 and July 2021 Phesi grew its clinical
research and clinical trial dataset from 13 million to 42 million
patients through a concerted effort in acquiring and structuring
data registries of de-identified data. At the same time, Sensyne,
through its unique ethical Strategic Research Agreement (SRA) model
that partners with healthcare systems, grew its real world patient
dataset from 6 million to over 18 million patients.
The combined international dataset now contains a high quality,
deep, longitudinal variety of structured de-identified and
anonymised data, in over 4,000 indications including rare
diseases.
The combined dataset, together with Sensyne's machine learning
expertise, provides deeper understanding of clinical trial and real
world patient populations which can improve the ability to select
the right patients for synthetic control arm clinical trials as
comparators to traditional clinical studies.
Specifically, the data can help in identifying relationships
between one disease and another and help in building predictive
models which contribute towards the development of synthetic
control arms, creating early warning systems for drugs in
development by helping indicate the drugs that may or may not work.
Such activity can de-risk trials, lower life science R&D costs
and reduce the time to market for effective drugs. Also,
critically, it can begin to limit the number of patients enrolled
in clinical trials that are exposed to placebos.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
"Sixty million patients is an important milestone in our journey
to create the world's best data resource for medical research.
However, it is the quality and depth of the data across many
disease areas and the combination of both clinical research data,
clinical trials data and longitudinal real world data from
electronic patient records, that makes the database such a powerful
tool for research professionals in both the life sciences and
healthcare sectors."
Dr Gen Li, President and Founder of Phesi Inc., said:
"Our mission is to harness the power of real-time dynamic data
to maximize successful outcomes in drug development, effectively
reduce patient burden, and accelerate the path of vital
therapeutics to patients. Together with Sensyne, we deliver a
volume, variety and velocity of data that makes this possible.
Integrated and advanced analytics, combined with real-world patient
and clinical trials data, enables us to de-risk trials and empowers
sponsors to adjust trials in real-time for the best outcomes.
Crucially, Phesi and Sensyne data address the ethical challenges of
clinical development by reducing the number of patients exposed to
placebos with synthetic control arms and further advances the
progress of smarter trials and faster cures."
In January 2021 Sensyne entered into an exclusive Strategic
Collaboration which included an equity investment in Phesi by
Sensyne of GBP10.0 million.
In May 2021 Sensyne announced its intention to build an
ethically-sourced real world dataset of c.100 million patient
records by the end of 2024. The 42 million Phesi clinical research
and clinical trial dataset does not form part of this 100 million
target.
-ENDS-
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, FMedSci,
Chief Executive Officer
Dr Richard Pye, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
+44 (0) 20 3709
Consilium Strategic Communications 5700
Mary-Jane Elliott
Jessica Hodgson
CSCSensynehealth@consilium-comms.com
About Sensyne Health www.sensynehealth.com
Sensyne Health plc Sensyne Health plc (LSE: SENS) is a clinical
artificial intelligence company operating a unique business model -
a for-profit plc making a positive social impact, sharing the
financial returns it makes with health systems. The company applies
clinical AI in the healthcare and life science industries. In
healthcare, Sensyne delivers remote patient monitoring and real
time decision making systems for healthcare organizations and their
patients. In life sciences, Sensyne analyses large complex
anonymised data sets to help life sciences companies accelerate the
development of new medicines.
About Phesi Inc. www.phesi.com
Phesi is a privately-owned, profitable virtual clinical
development company based in Connecticut, United States. The
company's mission is to enable data driven drug development and
commercialisation using predictive analytics powered by
patient-centric data science. Phesi's integrated offerings span the
entire clinical development process - from development planning and
indication assessment to protocol evaluation and design (including
synthetic control arm), site selection, and trial implementation
management. The company covers all to improve development plans,
protocol design and execution across all phases of clinical
development and a range of indications, including rare diseases,
partnering with life science companies to deliver novel therapies
faster and with cost savings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFSITTILIIL
(END) Dow Jones Newswires
August 02, 2021 02:00 ET (06:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024